Inside the industry’s quest for its next crowning achievement in oncology.
March 30 marks National Doctors’ Day, an annual holiday when we can all acknowledge and show appreciation for our physicians who help save lives everywhere.
These board additions will enhance the Company’s ability to execute on key corporate initiatives.
These seasoned industry professionals combined with the company’s newly strengthened balance sheet will drive key clinical programs.
Dr. George Gittes, the lead researcher and Harvard graduate that developed Genprex’s new potentially curative diabetes gene therapy, was featured in a video interview discussing the therapy.
A UPMC Children’s Hospital of Pittsburgh researcher is crediting a new, supportive environment for entrepreneurs at the University of Pittsburgh for making it possible to license a technology that may one day cure diabetes.
Genprex will present at the third annual LD Micro Virtual Conference on Wednesday, March 4 at 1:40 p.m. EST. Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company’s presentation and will be answering questions from investors.
Genprex is harnessing the power of a combinational treatment approach to overcome treatment limitations and offer patients new treatment options.
Austin-based biotech firm Genprex is looking for more growth after raising about $25.5 million through two recent stock offerings.
The Company intends to use the net proceeds from the offering to advance its drug development programs and for working capital and general corporate purposes.